MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024

MACROGENICS INC

Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.
Cash, equivalents & securities $229.8M as of Dec 31, 2023, up from $154.3M; cash runway into 2026.
Preliminary TAMARACK Phase 2 data for vobra duo in mCRPC expected at ASCO 2024; 177 patients enrolled.
Initiated Phase 1 dose escalation of MGC026 (topoisomerase I inhibitor-based ADC) in advanced solid tumors.
Received $100M from sale of TZIELD royalty interest and $50M milestone from Sanofi, recorded as $150.9M gain.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MACROGENICS INC reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 7, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-24-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.